Safety, Performance, and Clinical Benefit of Pacing the Left Bundle Branch Area - Post-Market Clinical Follow-up
← catalyst calendarNCT07209852 · readout in 1,108 d
Sponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
140estimated
Sites
13
Countries
Belgium, France, Germany +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-19 | actual | When the study began enrolling |
| Primary completion | 2029-08-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-08-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Bradycardia
- Atrioventricular Block
- Sinus Node Dysfunction
- Bundle-Branch Block
Intervention
- Device: Pacemaker lead — also filed as Bradycardia pacemaker system, Left Bundle Branch Area Pacing (LBBAP) Lead
Primary outcomes
what the primary-completion date above is the date OFLBBA Implant Success Rate
measured At the time of implant procedure (Day 0).
Maintenance of Ventricular Synchrony (Paced QRS Duration)
measured From implant through 3-year follow-up.
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed